Shanghai Xiao Fang Pharmaceutical Co.,Ltd. (SHA:603207)
China
· Delayed Price · Currency is CNY 27.95
-0.44 (-1.55%)
Mar 9, 2026, 4:00 PM EDT
SHA:603207 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Operating Revenue | 504.23 | 474.23 | 471.56 | 456.46 | 401.29 | 360.59 | Upgrade
|
| Other Revenue | 0.36 | 0.36 | 0.31 | 0.43 | 0.48 | 0.65 | Upgrade
|
| Revenue | 504.59 | 474.58 | 471.87 | 456.89 | 401.77 | 361.23 | Upgrade
|
| Revenue Growth (YoY) | 6.89% | 0.57% | 3.28% | 13.72% | 11.22% | 6.37% | Upgrade
|
| Cost of Revenue | 170.02 | 163.28 | 163.07 | 187.44 | 147.34 | 132.57 | Upgrade
|
| Gross Profit | 334.57 | 311.3 | 308.8 | 269.45 | 254.43 | 228.67 | Upgrade
|
| Selling, General & Admin | 74.33 | 60.57 | 59.47 | 54.65 | 95.06 | 40.03 | Upgrade
|
| Research & Development | 13.56 | 15.11 | 16.28 | 13.58 | 14.2 | 11.36 | Upgrade
|
| Other Operating Expenses | 3.61 | 1.91 | 2.4 | 4 | 3.01 | 2.15 | Upgrade
|
| Operating Expenses | 92.52 | 77.81 | 78.33 | 73.6 | 111.59 | 53.49 | Upgrade
|
| Operating Income | 242.05 | 233.49 | 230.48 | 195.85 | 142.84 | 175.18 | Upgrade
|
| Interest Expense | -0.01 | -0.03 | -0.05 | -0.07 | -0.09 | - | Upgrade
|
| Interest & Investment Income | 7.02 | 6.07 | 3.76 | 3.81 | 3.12 | 3.84 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.73 | -0.03 | -0.05 | -0.04 | -0.01 | -0.03 | Upgrade
|
| EBT Excluding Unusual Items | 249.79 | 239.5 | 234.14 | 199.55 | 145.85 | 178.98 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | 0.06 | 0.01 | 0.05 | 0.13 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | 0 | - | 0.25 | Upgrade
|
| Asset Writedown | -0.13 | - | - | - | -0.01 | - | Upgrade
|
| Other Unusual Items | -0.61 | 0.01 | 2.97 | 6.49 | 8.66 | 7.52 | Upgrade
|
| Pretax Income | 249.05 | 239.51 | 237.17 | 206.06 | 154.55 | 186.88 | Upgrade
|
| Income Tax Expense | 35.56 | 34.24 | 33.54 | 30.88 | 28.28 | 26.95 | Upgrade
|
| Net Income | 213.5 | 205.27 | 203.63 | 175.18 | 126.27 | 159.93 | Upgrade
|
| Net Income to Common | 213.5 | 205.27 | 203.63 | 175.18 | 126.27 | 159.93 | Upgrade
|
| Net Income Growth | 8.50% | 0.81% | 16.24% | 38.74% | -21.05% | 12.67% | Upgrade
|
| Shares Outstanding (Basic) | 160 | 134 | 120 | 120 | 120 | - | Upgrade
|
| Shares Outstanding (Diluted) | 161 | 134 | 120 | 120 | 120 | - | Upgrade
|
| Shares Change (YoY) | 29.43% | 12.01% | -0.17% | -0.22% | - | - | Upgrade
|
| EPS (Basic) | 1.34 | 1.53 | 1.70 | 1.46 | 1.05 | - | Upgrade
|
| EPS (Diluted) | 1.33 | 1.53 | 1.70 | 1.46 | 1.05 | - | Upgrade
|
| EPS Growth | -16.17% | -10.00% | 16.44% | 39.05% | - | - | Upgrade
|
| Free Cash Flow | 112.9 | 128.27 | 120.11 | 75.61 | 167.03 | 138.51 | Upgrade
|
| Free Cash Flow Per Share | 0.70 | 0.96 | 1.00 | 0.63 | 1.39 | - | Upgrade
|
| Dividend Per Share | 2.200 | 1.500 | - | - | - | - | Upgrade
|
| Gross Margin | 66.31% | 65.59% | 65.44% | 58.97% | 63.33% | 63.30% | Upgrade
|
| Operating Margin | 47.97% | 49.20% | 48.84% | 42.86% | 35.55% | 48.49% | Upgrade
|
| Profit Margin | 42.31% | 43.25% | 43.15% | 38.34% | 31.43% | 44.27% | Upgrade
|
| Free Cash Flow Margin | 22.38% | 27.03% | 25.45% | 16.55% | 41.57% | 38.34% | Upgrade
|
| EBITDA | 244.12 | 235.89 | 233.3 | 199.08 | 146.45 | 179.26 | Upgrade
|
| EBITDA Margin | 48.38% | 49.70% | 49.44% | 43.57% | 36.45% | 49.62% | Upgrade
|
| D&A For EBITDA | 2.08 | 2.4 | 2.83 | 3.24 | 3.61 | 4.08 | Upgrade
|
| EBIT | 242.05 | 233.49 | 230.48 | 195.85 | 142.84 | 175.18 | Upgrade
|
| EBIT Margin | 47.97% | 49.20% | 48.84% | 42.86% | 35.55% | 48.49% | Upgrade
|
| Effective Tax Rate | 14.28% | 14.29% | 14.14% | 14.99% | 18.30% | 14.42% | Upgrade
|
| Revenue as Reported | 504.59 | 474.58 | 471.87 | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.